Article
The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
Antimicrobial agents and chemotherapy - 17 May 2023
Xiao Meng A, Cleyle Jenna, Yoo Sunbin, Forrest Mekayla, Krullaars Zoë, Pham Hanh Thi, Mesplède Thibault
Abstract excerpt
Human immunodeficiency virus (HIV) treatment with antiretroviral regimens containing integrase strand transfer inhibitors such as dolutegravir (DTG) and bictegravir (BIC) offers high levels of protection against the development of drug resistance mutations. Despite this, resistance to DTG and BIC can occur through the development of the R263K integrase substitution. Failure with DTG has also been associated with...
Topics
Join the communities discussing this publication.